Skip to main content
. 2017 Dec 23;142(9):1911–1925. doi: 10.1002/ijc.31213

Figure 3.

Figure 3

Kaplan–Meier analysis of the prognostic value of Hsp70 expression (scores 0–2 vs. 3–4) and overall survival (OS) in subgroups of patients with p16‐, p53‐ and HPV16 DNA‐negative tumors. (a) Significant correlation of a low (scores 0–2) vs. high (scores 3–4) Hsp70 expression in FFPE tumor sections of SCCHN patients with p16‐negative tumors (N = 90) and OS. Patients at risk with Hsp70 scores 0–2 vs. 3–4 and a p16‐negative status at different time‐points after start of therapy ranging from 0 to 96 months are indicated below the graph. (b) Significant correlation of a low (scores 0–2) vs. high (scores 3–4) Hsp70 expression in FFPE tumor sections of SCCHN patients with p53‐negative tumors (N = 86) and OS. Patients at risk with Hsp70 scores 0–2 vs. 3–4 and a p53‐negative status at different time‐points after start of therapy ranging from 0 to 84 months are indicated below the graph. (c) Significant correlation of a low (scores 0–2) vs. high (scores 3–4) Hsp70 expression in FFPE tumor sections of SCCHN patients with HPV16 DNA‐negative tumors (N = 92) and OS. Patients at risk with Hsp70 scores 0–2 vs. 3–4 and a HPV16 DNA‐negative status at different time‐points after start of therapy ranging from 0 to 96 months are indicated below the graph.